Form 4: Nautilus CEO Sujal Patel Plans Future Stock Purchases

Nautilus Biotechnology's CEO, Sujal Patel, has pre-planned to increase his direct beneficial ownership in the company through future stock purchases totaling 200,000 shares.

Summary

• Sujal M. Patel, CEO, President, Secretary, Director, and 10% Owner of Nautilus Biotechnology, Inc. (NAUT), has filed a Form 4 indicating future planned stock purchases.
• On September 5, 2025, Mr. Patel plans to acquire 116,500 shares of Common Stock at a weighted average price of $0.6742 per share, with prices ranging from $0.6547 to $0.6899.
• Following this transaction, Mr. Patel's direct beneficial ownership will be 10,258,221 shares.
• On September 8, 2025, Mr. Patel plans to acquire an additional 83,500 shares of Common Stock at a weighted average price of $0.683 per share, with prices ranging from $0.6581 to $0.7145.
• After both planned transactions, Mr. Patel's direct beneficial ownership will total 10,341,721 shares.
• These transactions are made pursuant to a contract, instruction, or written plan for the purchase of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Mr. Patel also has indirect beneficial ownership of 1,814,035 shares through the Sujal Patel 2020 Children's Trust, where he and his spouse are trustees.
• Additionally, Mr. Patel indirectly owns 5,280,476 shares through PFV I, LLC, where he serves as the manager.

Sentiment

Score: 9

Explanation: The pre-planned future purchases by the CEO, who is also a Director and 10% owner, under a Rule 10b5-1 plan, represent a very strong signal of confidence in the company's long-term prospects and current valuation. This level of insider commitment is highly positive.

Positives

• The CEO, who is also a Director and 10% owner, is increasing his direct stake in the company, signaling strong confidence in its future prospects.
• The planned purchases are being executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled commitment to increase ownership.

Future Outlook

The planned insider purchases by the CEO suggest a positive internal outlook on the company's future performance and valuation.

Management Comments

• The act of the CEO, Sujal Patel, pre-planning significant stock purchases under a 10b5-1 plan serves as a strong implicit statement of confidence in Nautilus Biotechnology's future.

Industry Context

NA

Stakeholder Impact

• Shareholders may view the CEO's planned stock purchases as a strong vote of confidence, potentially leading to increased investor interest and positive sentiment.
• Employees may also interpret this as a positive sign regarding the company's stability and future growth prospects.

Key Dates

Recommendation

The CEO's pre-planned future purchases of a significant number of shares, executed under a Rule 10b5-1 plan, demonstrate a high level of confidence in Nautilus Biotechnology's long-term prospects and current valuation. This strong insider commitment at these price levels is a compelling positive signal for investors, suggesting the stock may be undervalued.

Keywords

Nautilus Biotechnology, NAUT, Sujal Patel, insider buying, stock purchase, Form 4, CEO, director, 10% owner, common stock, 10b5-1 plan